The only conclusion is that any benefit to AHZ shareholders from vaccines is a long way off.
The IP around ubiquitin with optimised RNA/DNA may be a different story.
I think WP referred to this as the "Money Shot" in the webinar.
Happy to be corrected
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-40
-
- There are more pages in this discussion • 311 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |